This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Senior, M. Biosimilars battle rages on, Amgen fights both sides. Nat Biotechnol 31, 269–270 (2013). https://doi.org/10.1038/nbt0413-269
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0413-269
This article is cited by
-
Biosimilars in IBD: from theory to practice
Nature Reviews Gastroenterology & Hepatology (2017)
-
First US biosimilar edges towards market
Nature Biotechnology (2015)
-
Biosimilars: Challenges and path forward
Biotechnology and Bioprocess Engineering (2014)